Psychometric validation of the work productivity and activity impairment questionnaire in ulcerative colitis: results from a systematic literature review

Journal of Patient-Reported Outcomes

Table 7 Responsiveness to treatment: change in WPAI scores following effective treatment interventions in prospective, open-label studies

				Change (mean WPAI scores at Week 8 - mean WPAI scores at baseline)
Study	N	Treatment regimen	Treatment duration	Absenteeism	Presenteeism	OWI	Activity Impairment
Travis 2017 [29]	446	ADA (initial 160/80 mg, 40 mg EOW at Week 4)	26 weeks	−11.4	−24.5	− 29.2	−27.2
Willshire 2014 [40]	404	MMX mesalamine 4.8 g/day	8 weeks	− 7.6	−20.6	−23.4	−24.1
Yarlas 2015a [36]	103	MMX mesalamine 2.4–4.8 g/day	8 weeks	− 4.0	−12.3	− 13.8	−14.2
Weighted mean change^a				*− 9.0*	*−21.5*	*−25.1*	*−24.5*
Median change				*−7.6*	*− 20.6*	*−23.4*	*−24.1*

ADA adalimumab, EOW every other week, MMX multimatrix, OWI Overall Work Impairment, WPAI Work Productivity and Activity Impairment questionnaire
Values printed in BOLD indicating those exceeding established thresholds indicating clinically important change
^aWeighted by sample size